Table 1 B cell lymphoma cell panel cell lines, specifics and mutational information.

From: Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies

Cell line

Specifics

MYC translocation

BCL2 or 6 translocation

p53 status

Ref.

Namalwa

Burkitt Lymphoma (EBV)

+

-

Mutant

[44]

RAMOS

Burkitt Lymphoma

+

-

Mutant

[45]

CA46

Burkitt Lymphoma

+

-

Mutant

[46]

DG75

Burkitt Lymphoma

+

-

Mutant

[47]

ST486

Burkitt Lymphoma (EBV)

+

-

Mutant

[46]

OCI-Ly3

Diffuse Large B-cell Lymphoma (ABC)

-

BCL2 (CNG)

WT

[48, 49]

U2932

Diffuse Large B-cell Lymphoma (ABC)

-

BCL2, BCL6

Mutant

[50]

SC-1

Diffuse Large B-cell Lymphoma (GCB)

+

BCL2

Mutant

[48, 51]

SUDHL4

Diffuse Large B-cell Lymphoma (GCB)

+

BCL2, BCL6

Mutant

[48, 52, 53]

SUDHL5

Diffuse Large B-cell Lymphoma (GCB)

+

BCL2

WT

[52, 53]